share_log

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5：募资说明书
美股SEC公告 ·  2024/05/06 21:19

Moomoo AI 已提取核心信息

Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $20,000,000. This update, detailed in a prospectus supplement filed on May 6, 2024, follows the company's public float surpassing $75.0 million on May 2, 2024, which lifted the previous sales limitation under General Instruction I.B.6 of Form S-3. Prior to this amendment, Allarity Therapeutics was restricted to selling up to $18,000,000 worth of common stock. As of May 2, 2024, the company had already sold 10,835,422 shares for gross proceeds of $16,054,081. The new prospectus supplement allows for the sale of additional shares up to the new $20,000,000 limit, inclusive of the gross proceeds already obtained through the Sales Agreement.
Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $20,000,000. This update, detailed in a prospectus supplement filed on May 6, 2024, follows the company's public float surpassing $75.0 million on May 2, 2024, which lifted the previous sales limitation under General Instruction I.B.6 of Form S-3. Prior to this amendment, Allarity Therapeutics was restricted to selling up to $18,000,000 worth of common stock. As of May 2, 2024, the company had already sold 10,835,422 shares for gross proceeds of $16,054,081. The new prospectus supplement allows for the sale of additional shares up to the new $20,000,000 limit, inclusive of the gross proceeds already obtained through the Sales Agreement.
Allarity Therapeutics Inc.宣布修订其与Ascendiant Capital Markets, LLC的销售协议，将其可能发行和出售的普通股总额增加到2,000万美元。2024年5月6日提交的招股说明书补充文件详细介绍了这一更新，此前该公司于2024年5月2日公开持股量超过7,500万美元，这取消了先前根据S-3表格I.B.6号一般指令规定的销售限制。在此修正案之前，Allarity Therapeutics仅限于出售价值不超过1800万美元的普通股。截至2024年5月2日，该公司已经出售了10,835,422股股票，总收益为16,054,081美元。新的招股说明书补充文件允许在新的20,000,000美元限额内出售额外股份，其中包括通过销售协议获得的总收益。
Allarity Therapeutics Inc.宣布修订其与Ascendiant Capital Markets, LLC的销售协议，将其可能发行和出售的普通股总额增加到2,000万美元。2024年5月6日提交的招股说明书补充文件详细介绍了这一更新，此前该公司于2024年5月2日公开持股量超过7,500万美元，这取消了先前根据S-3表格I.B.6号一般指令规定的销售限制。在此修正案之前，Allarity Therapeutics仅限于出售价值不超过1800万美元的普通股。截至2024年5月2日，该公司已经出售了10,835,422股股票，总收益为16,054,081美元。新的招股说明书补充文件允许在新的20,000,000美元限额内出售额外股份，其中包括通过销售协议获得的总收益。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Nutriband
    NTRB
    -- 7.340
    Eterna Therapeutics
    ERNA
    -- 0.635
    Tonix Pharmaceuticals
    TNXP
    -- 0.3190
    ImmunoPrecise Antibodies
    IPA
    -- 0.645
    Sonnet BioTherapeutic
    SONN
    -- 2.0000
    解锁完整榜单
    热门中概股
    追踪最热门的中概股实时资讯。
    热门讨论
    12月CPI数据助推降息预期，美股能否延续强势？
    美国12月CPI同比上涨2.9%，符合预期，但已连续三个月呈现上涨趋势。市场对此反应积极，因为剔除食品和能源价格的核心CPI上涨了3.2%，是自2021年以来的最低读数之一。12月PPI增长3.3%，低于预期的3.5%。美联储目标在2025年实现2.5%的通胀率，但密歇根调查数据 展开
    这是十二月消费指数的详细情况，一览无余